Curiosis KRX:494120KOSDAQ

큐리오시스 · Korean news coverage and regulatory filings, organized.

Articles, 24h4
Articles, 7 days4
DART filings, 7 days0
Articles tracked4since Sep 11

In Q2 2026, Curiosis reported revenue of ₩3.5bn, up 72.9% year on year, and an operating loss of ₩1.9bn. Curiosis (큐리오시스) appeared in 4 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 15 with 4 articles. The most common catalyst was tech & capacity (1).

Curiosis quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩3.5bn+72.9%−₩1.9bn−₩2.1bn
Q1 2026₩1.1bn-25.5%−₩1.6bn−₩1.5bn
Q4 2025 derived₩2.7bn+66.8%−₩2.3bn−₩2.3bn
Q3 2025₩1.2bn-25.3%−₩2.1bn−₩2.1bn
Q2 2025₩2.0bn+53.5%−₩1.3bn−₩1.3bn
Q1 2025₩1.5bn+60.5%−₩1.8bn−₩2.2bn
Q4 2024 derived₩1.6bn−₩2.3bn−₩639m
Q3 2024₩1.5bn−₩1.1bn−₩1.3bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.

Curiosis top stories 2 weeks, by number of outlets

  1. 1
    큐리오시스-AI신약연구원, 자율실험실 인재 양성 맞손
    2 outlets · 2 articlesFirst report Sep 15 09:59 메디파나뉴스
  2. 2
    큐리오시스, 한국제약바이오협회와 AI신약개발 협력
    1 outlets · 1 articlesFirst report Sep 15 09:24 뉴스핌Partnership
  3. 3
    큐리오시스, AI신약연구원과 5년간 AI 신약개발 인재 양성
    1 outlets · 1 articlesFirst report Sep 15 09:23 바이오타임즈

Latest Curiosis news Korean headlines